Form 4 Filing for Aligos Therapeutics, Inc.

This filing details a Form 4 submission for Aligos Therapeutics, Inc. (ALGS) on June 29, 2026, reporting on behalf of director Carole Nuechterlein. The transaction, dated June 25, 2026, involves the acquisition of 5,860 stock options with a right to buy common stock. These options have an exercise price of $5.50 and expire on June 25, 2036. The shares subject to the option will vest and become exercisable on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027, contingent upon continuous service to the issuer. Following this transaction, Ms. Nuechterlein holds 5,860 shares of common stock underlying the options.